Finland· FI-REL-REL43273
Neuraceq
A florbetaben (18f) product containing florbetaben f18, registered in Finland by Lantheus Germany GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Florbetaben (18f) is registered in 11 of 19 countries.
Countries holding a registration under ATC V09AX06 (florbetaben (18f)), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Florbetaben (18f) · ATC V09AX06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Florbetaben F18
- Manufacturer
- Lantheus Germany GmbH
- Country
- Finland (FI)
- ATC code
- V09AX06
- ATC class
- Florbetaben (18F)
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Florbetaben (18f) in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesNeuraceqLantheus Biosciences Ltd.
- CanadaNEURACEQISOLOGIC INNOVATIVE RADIOPHARMACEUTICALS LTD.
- CzechiaNEURACEQLantheus Germany GmbH, Berlín
- SpainNEURACEQ 300 MBq/ml solucion inyectableLantheus Germany Gmbh
- BelgiumNeuraceq 300 MBq/mlLantheus Germany
- NetherlandsNeuraceq 300 MBq/mL, oplossing voor injectieLife Molecular Imaging GmbH
- SwedenNeuraceq 300 MBq/ml Injektionsvätska, lösningLantheus Germany GmbH
- United KingdomNeuraceq [F-18] 300MBq solution for injection vialsLantheus Biosciences Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Neuraceq
- Liechtenstein · Neuraceq
- Norway · Neuraceq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0fc8d13b-e74a-42a6-9177-592502f88e0b GET /v1/drugs/0fc8d13b-e74a-42a6-9177-592502f88e0b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, liuos",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "300 MBq/ml",
"atc_label": "florbetabeeni(18F)",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/13/906/001",
"fimea_rel_id": "REL43273",
"authorised_at": "2014-02-20"
}See everything about florbetaben (18f).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.